Valve Material with Combined Anti-Clotting and Anti-Calcification Properties

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted Patent US12589187B2 to Jilin Venus Haoyue Medical Limited for a valve material with synergistic anti-coagulation and anti-calcification functions. The patent describes a preparation method involving glutaraldehyde cross-linking treatment, amine compound blocking, and anticoagulant cross-linking that addresses calcification and thrombosis issues in biological valve materials.

View original document View source feed page

What changed

The USPTO granted Patent US12589187B2 for a valve material with combined anti-clotting and anti-calcification properties developed by Jilin Venus Haoyue Medical Limited. The patent (14 claims) covers a preparation method involving glutaraldehyde cross-linking treatment, immersion in an amine compound blocking solution for 0.5-6 hours, followed by cross-linking with an anticoagulant and cross-linking agent for 6-24 hours at 4°C-37°C. The resulting valve material is stored in a mixed solvent of glutaraldehyde or isopropyl alcohol/glycerol and can be used for aortic, pulmonary, venous, mitral, and tricuspid valve replacement.

This is a patent grant notice conveying intellectual property rights, not a regulatory action imposing compliance obligations. Medical device manufacturers developing bioprosthetic heart valves may want to review the patent claims to assess potential licensing needs or design differentiation strategies. No compliance deadlines or penalties are associated with this document.

Source document (simplified)

← USPTO Patent Grants

Valve material with combined anti-clotting and anti-calcification properties and preparation method

Grant US12589187B2 Kind: B2 Mar 31, 2026

Assignee

Jilin Venus Haoyue Medical Limited

Inventors

Yunbing Wang, Li Yang, Rifang Luo, Linhua Li

Abstract

The present invention provides a valve material having synergistic anti-coagulation and anti-calcification functions and a preparation method therefor. The preparation method comprises the following steps: performing glutaraldehyde cross-linking treatment on an animal-derived biological valve material; immersing the treated valve material in a blocking solution containing an amine compound for 0.5-6 h, thereby blocking the remaining aldehyde groups after glutaraldehyde cross-linking; then placing the valve material into a reaction solution containing an anticoagulant and a cross-linking agent, and performing cross-linking treatment for 6-24 h at 4° C.-37° C.; and finally washing and obtaining the valve material, and storing the valve material in a mixed solvent of glutaraldehyde or isopropyl alcohol/glycerol. The method can effectively solve the problem of calcification and thrombosis caused by residual aldehyde groups in a valve material prepared by the existing method. The valve material prepared by the present method can be used as a valve material required for aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

CPC Classifications

A61L 27/3687 A61L 27/3625 A61L 27/3629 A61L 2300/236 A61L 2300/252 A61L 2300/418 A61L 2300/42 A61L 27/3641 A61L 2400/02 A61L 2430/20 A61L 27/507 A61L 27/54 A61L 33/0011 A61L 33/0041 A61L 33/0082 A61L 33/08 A61L 33/128 A61L 27/3604 A61L 2300/232 A61L 2400/18 A61L 2430/40 C12N 5/0697